Skip to main content
. 2014 Oct;134(4):686–695. doi: 10.1542/peds.2014-0571

FIGURE 1.

FIGURE 1

Samples available for study. A, Patients evaluable for PPV-23 response (vaccinated with PPV-23 with ≥1 preimmunization and 1 postimmunization sample for measurement of pneumococcal antibody levels). B, Vaccinated participants with ≥1 blood sample after immunization for measurement of MMR antibody levels. C, Patients who received randomized treatment before MMR vaccination and evaluable for acute MMR response (with ≥1 blood sample for measurement of MMR antibody levels within the 2- to 10-week acute response window).